A Clinicopathologic Study of Thirty Cases of Acquired Perforating Dermatosis in Korea
Overview
Authors
Affiliations
Background: Acquired perforating dermatosis (APD) is histopathologically characterized by transepidermal elimination of materials from the upper dermis. APD can be divided into four diseases: Kyrle's disease, perforating folliculitis, elastosis perforans serpiginosa, and reactive perforating collagenosis. APD is usually associated with systemic diseases, especially diabetes mellitus or chronic renal failure. So far, there have only been a few Korean studies of APD, which have a limited number of patients.
Objective: The aim of this study is to evaluate the clinical and histopathologic characteristics of 30 cases of APD and to examine the association with systemic diseases.
Methods: We retrospectively reviewed the medical records and biopsy specimens of 30 patients who were diagnosed with APD.
Results: The mean age was 55.5 years, and the average duration of the lesion was 7.8 months. The lower extremities (73.3%) were the most frequently occurring sites of the lesion. Twenty-five patients (83.3%) had pruritus, and Koebner's phenomenon was present in 11 patients. Patients of 63.3% had at least one systemic disease. Diabetes mellitus (n=17, 56.7%) and chronic renal failure (n=10, 33.3%) were the most commonly associated conditions. Most patients received topical steroids (93.3%) and antihistamines (80.0%). The most common histopathologic type was reactive perforating collagenosis (n=23, 73.3%).
Conclusion: In this study, most patients had a systemic association to the diseases. Therefore, we suggest that further evaluation is necessary for patients who present with APD. This includes reviewing patient's comprehensive past medical history, clinical exam, and additional diagnostic testing to check for the possibility of associated systemic diseases.
A case of acquired reactive perforating collagenosis after COVID-19 infection.
Wang S, Min X, Wang X, Cheng L, Qiu L Postepy Dermatol Alergol. 2024; 41(5):536-537.
PMID: 39606609 PMC: 11589641. DOI: 10.5114/ada.2024.142575.
A case report on acquired reactive perforating collagenosis.
Su Y, Cui W Medicine (Baltimore). 2024; 103(29):e39071.
PMID: 39029035 PMC: 11398783. DOI: 10.1097/MD.0000000000039071.
A potential new treatment with upadacitinib for acquired reactive perforating collagenosis.
Ding W, Wang Y, Song L, Zhou N JAAD Case Rep. 2024; 48:112-114.
PMID: 38813063 PMC: 11134568. DOI: 10.1016/j.jdcr.2024.04.017.
Edek Y, Aypek Y, Ogut B, Erdem O, Adisen E Dermatol Pract Concept. 2024; 14(2).
PMID: 38810077 PMC: 11135951. DOI: 10.5826/dpc.1402a100.
Acquired perforating dermatosis associated with risankizumab.
Alhadlg M, Alhammad G, Madani A JAAD Case Rep. 2024; 45:88-90.
PMID: 38434600 PMC: 10907506. DOI: 10.1016/j.jdcr.2024.01.023.